Retatrutide is an investigational multi‑agonist medication that activates GLP‑1, GIP, and glucagon receptors. This combined approach is being studied for its potential to influence appetite, metabolism, and energy balance more broadly than single‑pathway therapies.

Early clinical trials have shown notable reductions in body weight and improvements in metabolic markers such as glucose and lipid levels. These findings are preliminary, and researchers continue to evaluate long‑term safety, tolerability, and effectiveness.

Retatrutide is not yet approved for clinical use, and its future availability depends on ongoing research and regulatory review. Healthcare professionals emphasize that any metabolic therapy should be used under medical guidance as evidence continues to develop.